Sales Battle Card: Nilo Therapeutics $101M Series A
Flush with a $101M Series A, Nilo Therapeutics is gearing up to scale R&D. This battle card gives you Kim Seth’s contact, core pain points, competitor intel, and a do-now checklist to fuel your pipeline and close the deal.
Published on
Do not index
Do not index
🚀 Battle Card: Nilo Therapeutics
Quick trigger:
👤 Decision Maker in the News
- Kim Seth, CEO 📧 kim@nilotx.com
💡 Why It Matters
- This Nilo Therapeutics sales trigger means they’re flush with capital and gearing up to scale R&D infrastructure. → Source
🎯 Core Pain Point
- Limited preclinical assay capacity for neural circuit-based immunotherapies
- Urgent need to fast-track preclinical-to-clinical transition
💰 What to Pitch
- Primary: Preclinical CRO services → rapid assay deployment (capitalize on the Nilo Therapeutics sales trigger)
- Expansion: Clinical trial management platform → streamlined multi-site trials
🗺️ Quick Context
- HQ: New York, NY, US
- Employees: ≈ 60
- Rev: ≈ $0 (pre-revenue)
- Website: nilotx.com
🤼 Competitive Intel
*Which other vendors you’ll probably face to win Nilo Therapeutics’s business.*
- Charles River Laboratories — Preclinical CRO
- Unique edge: deep immunology assay portfolio
- Evaluated by VP R&D for preclinical expertise
- Labcorp — Clinical development services
- Unique edge: end-to-end trial management
- Evaluated by Dir. Clinical Ops for global trial reach
- IQVIA — Data analytics & clinical trials
- Unique edge: integrated data analytics platform
- Evaluated by VP Data Science for predictive insights
- Thermo Fisher Scientific — Lab equipment & consumables
- Unique edge: comprehensive assay kits
- Evaluated by Lab Managers for throughput
- Parexel — Full-service CRO
- Unique edge: regulatory strategy expertise
- Evaluated by CEO/CFO for compliance assurance
✅ Do-Now Checklist
Connect with Kim Seth on email and reference the Nilo Therapeutics sales trigger
Frame first outreach referencing this Nilo Therapeutics sales trigger to grab their attention
Reference the Nilo Therapeutics sales trigger in LinkedIn teasers and email subject lines
Schedule follow-ups in CRM (Day 3 & Day 10)
Next Step
🧠 Copy My Prompt for Personalized Cold Outreach
────────────────────────────
✏️ YOUR COMPANY
────────────────────────────
OUR_COMPANY = ❑<your company>❑
OFFER_BRIEF = ❑Rapid preclinical CRO services❑
PROOF_METRIC = ❑50% faster assay results❑
CTA_STYLE = ❑quick_call❑
TONE = ❑friendly❑
────────────────────────────
📌 TARGET COMPANY
────────────────────────────
NAME = Kim
COMPANY = Nilo Therapeutics
DEPT = R&D
SIZE = 60
BOTTLENECK = limited preclinical assay capacity
EVENT = $101M Series A financing
DETAIL = launch & $101M Series A financing
PAIN = urgent need to fast-track preclinical-to-clinical transition
SRC = https://vcnewsdaily.com/nilo-therapeutics/venture-capital-funding/lcclqqdvkh
SIM_CO = Cerevance
WIN_METRIC = 50% faster assay results
NEXT_SIZE = 100
EMP_EST = ≈ 60
REV_EST = ≈ $0
────────────────────────
TASK FOR CHATGPT
────────────────────────
Role: “NewsletterForLeads SDR-Assist”.
Validate any ≈ guesses via SRC.
EMAIL (keep breaks):
Subject: 60-person R&D
Kim—noticed your R&D team is ≈ 60.
That’s when limited preclinical assay capacity slows growth.
We helped Cerevance fix this with Rapid preclinical CRO services.
Result: 50% faster assay results.
Quick call?
PS—next bottleneck hits ≈ 100.
DM ≤45 words, TONE:
Saw your post about launch & $101M Series A financing — urgent need to fast-track preclinical-to-clinical transition.
Rapid preclinical CRO services. 50% faster assay results.
Quick chat?